In patients with SSc, the upregulation of B-cell activating factors and the abnormality of B-cell homeostasis make targeting CD19+ B cells a potential therapeutic strategy that could induce a more profound immune system reprogramming. This evidence concerns the gene CD19 and systemic sclerosis.